[go: up one dir, main page]

ATE388958T1 - 4'-c-substituierte 2-haloadenosinderivate - Google Patents

4'-c-substituierte 2-haloadenosinderivate

Info

Publication number
ATE388958T1
ATE388958T1 AT05006326T AT05006326T ATE388958T1 AT E388958 T1 ATE388958 T1 AT E388958T1 AT 05006326 T AT05006326 T AT 05006326T AT 05006326 T AT05006326 T AT 05006326T AT E388958 T1 ATE388958 T1 AT E388958T1
Authority
AT
Austria
Prior art keywords
substituted
haloadenosine
derivative
derivatives
provides
Prior art date
Application number
AT05006326T
Other languages
English (en)
Inventor
Satoru Kohgo
Hiroshi Ohrui
Eiichi Kodama
Masao Matsuoka
Hiroaki Mitsuya
Original Assignee
Yamasa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamasa Corp filed Critical Yamasa Corp
Application granted granted Critical
Publication of ATE388958T1 publication Critical patent/ATE388958T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT05006326T 2004-03-24 2005-03-23 4'-c-substituierte 2-haloadenosinderivate ATE388958T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004087198 2004-03-24
JP2004263409 2004-09-10

Publications (1)

Publication Number Publication Date
ATE388958T1 true ATE388958T1 (de) 2008-03-15

Family

ID=34934441

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05006326T ATE388958T1 (de) 2004-03-24 2005-03-23 4'-c-substituierte 2-haloadenosinderivate

Country Status (8)

Country Link
US (3) US7339053B2 (de)
EP (1) EP1589026B1 (de)
JP (2) JP4253342B2 (de)
AT (1) ATE388958T1 (de)
CA (1) CA2502109C (de)
DE (1) DE602005005240T2 (de)
ES (1) ES2300892T3 (de)
WO (1) WO2005090349A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60336441D1 (de) 2002-09-02 2011-05-05 Samsung Electronics Co Ltd Kontaktstruktur für eine Halbleitervorrichtung, dünnschichtige Transistoranordnung mit einer solchen Kontaktstruktur und dessen Herstellungsmethode
CA2502109C (en) * 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
US11696908B2 (en) 2007-01-31 2023-07-11 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters
US9636317B2 (en) 2007-01-31 2017-05-02 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters
US9533938B2 (en) 2007-01-31 2017-01-03 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters for the treatment of stroke
EP2170053A4 (de) 2007-01-31 2010-06-23 Biosuccess Biotech Company Zusammensetzungen und verfahren für die verwendung von phorbolestern
US11564901B2 (en) 2007-01-31 2023-01-31 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters
US10369222B2 (en) 2012-01-18 2019-08-06 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters for the treatment of stroke
US9974764B2 (en) 2007-01-31 2018-05-22 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters in the treatment of neoplasms
KR101156330B1 (ko) 2007-02-13 2012-06-13 미쓰비시덴키 가부시키가이샤 표시 장치 및 그 제조 방법
US10099996B2 (en) 2012-01-18 2018-10-16 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters in the treatment of neoplasms
US9550722B2 (en) 2012-01-18 2017-01-24 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbal esters for the treatment of stroke
JP6191989B2 (ja) * 2014-02-12 2017-09-06 学校法人東京理科大学 アデニン誘導体又はその薬理学的に許容しうる塩、その製造方法、及びその用途
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
MA41213A (fr) * 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
US10953029B2 (en) 2015-09-23 2021-03-23 Merck Sharp & Dohme Corp. 4′-Substituted nucleoside reverse transcriptase inhibitors and preparations thereof
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
RU2755130C2 (ru) 2016-05-12 2021-09-13 Мерк Шарп И Доум Корп. Система доставки лекарств для доставки противовирусных средств
EP3471829A4 (de) * 2016-06-20 2020-01-15 Merck Sharp & Dohme Corp. Wirkstofffreisetzungssystem zur freisetzung von viruziden
EP3543238B1 (de) 2016-11-16 2021-05-19 National Center for Global Health and Medicine Nukleosidderivate mit antiviraler aktivität
WO2018191093A1 (en) 2017-04-10 2018-10-18 Merck Sharp & Dohme Corp. Drug delivery system for the delivery of antiviral agents
US20200138845A1 (en) * 2017-07-18 2020-05-07 Viiv Healthcare Company Combination Drug Therapy
US11040975B2 (en) 2017-12-08 2021-06-22 Merck Sharp & Dohme Corp. Carbocyclic nucleoside reverse transcriptase inhibitors
WO2019171285A1 (en) * 2018-03-07 2019-09-12 Glaxosmithkline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
WO2019217973A1 (en) 2018-05-11 2019-11-14 Rhode Island Hospital Compositions and methods for treating articulating joint disorders with nucleoside reverse transcriptase inhibitors
US12297224B2 (en) * 2018-07-02 2025-05-13 Henan Genuine Biotech Co., Ltd. Crystal form, preparation method, and application of 4'-substituted nucleoside
EP3820473A4 (de) 2018-07-09 2022-05-11 Merck Sharp & Dohme Corp. Enzymatische synthese von 4'-ethinylnukleosidanaloga
BR112021002169A2 (pt) * 2018-08-09 2021-05-04 Glaxosmithkline Intellectual Property (No.2) Limited compostos úteis na terapia do hiv
EP3844164A1 (de) * 2018-08-30 2021-07-07 GlaxoSmithKline Intellectual Property (No.2) Limited Verbindungen zur verwendung in der hiv-therapie
MX2021007544A (es) * 2018-12-20 2021-08-11 Merck Sharp & Dohme Llc Nuevas formas cristalinas de un compuesto inhibidor de la translocacion de la transcriptasa inversa de nucleosidos.
MX2021008751A (es) 2019-01-25 2021-11-12 Univ Brown Composiciones y metodos para tratar, prevenir o revertir la inflamacion y los trastornos asociados a la edad.
MA55200A (fr) * 2019-03-06 2022-01-12 Glaxosmithkline Ip No 2 Ltd Composés utiles dans la thérapie du vih
US12391694B2 (en) 2019-06-24 2025-08-19 Merck Sharp & Dohme Llc Process for the preparation of 2-fluoroadenine
WO2021021717A1 (en) * 2019-07-27 2021-02-04 Brii Biosciences, Inc. Adenosine derivative and pharmaceutical composition comprising the same
EP4010349A1 (de) * 2019-08-08 2022-06-15 GlaxoSmithKline Intellectual Property (No. 2) Limited 4'-ethynyl-2'-deoxyadenosinderivate und ihre verwendung in der hiv-therapie
CN114206336A (zh) * 2019-08-13 2022-03-18 默沙东公司 用于递送抗病毒剂的药物递送系统
WO2021038509A1 (en) * 2019-08-28 2021-03-04 Glaxosmithkline Intellectual Property (No.2) Limited 4'-ethynyl-2'-deoxyadenosine derivatives and their use in hiv therapy
PE20221036A1 (es) * 2019-09-11 2022-06-17 Scripps Research Inst Profarmacos antivirales y formulaciones de los mismos
AR121620A1 (es) * 2020-03-20 2022-06-22 Gilead Sciences Inc Profármacos de nucleósidos 4’-c-sustituidos-2-halo-2’-deoxiadenosina y métodos de preparación y uso de los mismos
WO2021225869A1 (en) * 2020-05-05 2021-11-11 BEELER, Nicole, M. Drug delivery system for the delivery of antiviral agents and contraceptives
EP4281081A4 (de) 2021-01-25 2025-05-14 Brii Biosciences, Inc. Adenosinderivat und pharmazeutische zusammensetzung damit
US11890297B2 (en) 2021-01-25 2024-02-06 Brii Biosciences, Inc. Combination therapy for HIV with adenosine derivative and capsid inhibitors
JP2024507550A (ja) * 2021-02-23 2024-02-20 ヴィーブ、ヘルスケア、カンパニー Ｈｉｖ療法に有用な化合物
WO2022271878A1 (en) * 2021-06-22 2022-12-29 Rome Therapeutics, Inc. 4-ethynyl-3-hydroxy-tetrahydrofuranyl-adenine phosphoramidates and related compounds and their use in treating medical conditions
EP4493573A1 (de) 2022-03-15 2025-01-22 Rome Therapeutics, Inc. Verbindungen und verfahren zur behandlung von krankheiten

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192749A (en) * 1990-05-21 1993-03-09 Syntex (U.S.A.) Inc. 4'-substituted nucleosides
JP4076114B2 (ja) * 1999-05-12 2008-04-16 ヤマサ醤油株式会社 ４’−ｃ−エチニルプリンヌクレオシド化合物
DE60005501T2 (de) * 1999-05-12 2004-06-24 Yamasa Corp., Choshi 4'-c-ethynyl-pyrimidine nukleoside
JPWO2003068796A1 (ja) 2002-02-15 2005-06-02 ヤマサ醤油株式会社 ４’−ｃ−シアノ−２’−デオキシプリンヌクレオシド
EA012844B1 (ru) * 2003-02-19 2009-12-30 Йельский Университет Аналоги противовирусных нуклеозидов и способы лечения вирусных инфекций, в частности вич-инфекций
CA2502109C (en) * 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative

Also Published As

Publication number Publication date
DE602005005240T2 (de) 2009-03-12
US7625877B2 (en) 2009-12-01
DE602005005240D1 (de) 2008-04-24
JP4253342B2 (ja) 2009-04-08
JP2011256173A (ja) 2011-12-22
WO2005090349A1 (ja) 2005-09-29
US20090234110A1 (en) 2009-09-17
ES2300892T3 (es) 2008-06-16
US8039614B2 (en) 2011-10-18
CA2502109C (en) 2010-02-23
US7339053B2 (en) 2008-03-04
CA2502109A1 (en) 2005-09-24
EP1589026A1 (de) 2005-10-26
US20080153774A1 (en) 2008-06-26
JPWO2005090349A1 (ja) 2008-01-31
US20050215512A1 (en) 2005-09-29
EP1589026B1 (de) 2008-03-12
JP5213194B2 (ja) 2013-06-19

Similar Documents

Publication Publication Date Title
ATE388958T1 (de) 4'-c-substituierte 2-haloadenosinderivate
AP1753A (en) Thiophene derivatives as antiviral agents for flavvivirus infection
DE60210944D1 (de) N-substituierte heterocyclische nichtaryl-nmda/nr2b-antagonisten
DE60032780D1 (de) Tetrahydroquinolin-derivate
AU3599701A (en) Fluorescent probes for the quantitation of zinc
DE602004009200D1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
ATE503746T1 (de) Neue imidazolidinderivate
TW200738667A (en) Preparation method for dioxan-2-ylalkylcarbamate derivatives and intermediate thereof
BRPI0409376A (pt) derivados de indeno como agentes farmacêuticos
IL169184A0 (en) Aromatic compounds as anti-inflammatory, immunomdulatory and anti-proliferatory agents
NO20052074L (no) Substituerte benzoksazinoner og anvendelser derav.
MY138826A (en) 2,7-substituted indoles
TW200744589A (en) Pharmaceutical composition
PL1845780T3 (pl) Zastosowanie pochodnych metylofenidatu
DE60239491D1 (de) Thiazolidindionderivate und diese enthaltende pharmazeutische zusammensetzung
EA200801139A1 (ru) Композиция для аэрозольной ингаляции
AR034313A1 (es) Utilizacion de derivados de piridoindolona para la preparacion de medicamentos
MXPA03008725A (es) Medicamentos para hiperactividad vesicular.
WO2004093796A3 (en) Lactam derivatives and methods of their use
DE602006013828D1 (en) 4-aryloxy-chinolin-derivate als 5-ht6-modulatoren
DK1433480T3 (da) Lægemiddel indeholdende pyrimidin-derivat
EP1557407A4 (de) Neue alpha-ketoamidderivate und deren verwendung
AU2002214266A1 (en) Carbamate derivatives, process for producing the same and use thereof
EP1325913A3 (de) Piperidincarbonsäuramid-Derivate
TH103345A (th) อนุพันธ์ 3-ไซยาโน-ควิโนลีนที่มีกิจกรรมต้านการงอกขยาย

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1589026

Country of ref document: EP